Boothbay Fund Management LLC Sells 146,543 Shares of Evolus, Inc. $EOLS

Key Points

• Boothbay Fund Management LLC has reduced its stake in Evolus, Inc. by 11.4%, now holding approximately $13.73 million in the company's stock after selling over 146,000 shares.
• The company has a market capitalization of $477.34 million and is currently trading at $7.38, with a one-year price range between $5.71 and $17.82.
• Recent analyst ratings show a consensus of "Moderate Buy" for Evolus, with price targets varying from $18.00 to $22.00 based on recent reports.

Boothbay Fund Management LLC lessened its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 11.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,141,224 shares of the company's stock after selling 146,543 shares during the quarter. Boothbay Fund Management LLC owned about 1.77% of Evolus worth $13,729,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of EOLS. AlphaQuest LLC purchased a new stake in shares of Evolus during the first quarter valued at approximately $39,000. State of Wyoming increased its stake in Evolus by 988.1% during the 1st quarter. State of Wyoming now owns 3,754 shares of the company's stock worth $45,000 after buying an additional 3,409 shares during the period. IFP Advisors Inc increased its stake in Evolus by 99.0% during the 1st quarter. IFP Advisors Inc now owns 9,427 shares of the company's stock worth $113,000 after buying an additional 4,691 shares during the period. Rafferty Asset Management LLC acquired a new position in Evolus in the 4th quarter worth $115,000. Finally, Man Group plc purchased a new position in Evolus in the 4th quarter valued at about $121,000. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Stock Performance

Shares of EOLS traded down $0.12 during midday trading on Tuesday, hitting $7.49. 408,611 shares of the stock traded hands, compared to its average volume of 1,084,751. Evolus, Inc. has a 1-year low of $5.71 and a 1-year high of $17.82. The company has a debt-to-equity ratio of 22.00, a quick ratio of 1.86 and a current ratio of 2.27. The firm has a market capitalization of $484.45 million, a PE ratio of -7.72 and a beta of 1.07. The business's 50 day moving average price is $8.23 and its two-hundred day moving average price is $10.08.

Insider Buying and Selling at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the sale, the chief marketing officer directly owned 89,949 shares in the company, valued at $675,516.99. The trade was a 5.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brady Stewart bought 30,000 shares of the company's stock in a transaction dated Friday, August 15th. The stock was purchased at an average cost of $6.82 per share, for a total transaction of $204,600.00. Following the completion of the transaction, the director owned 88,629 shares of the company's stock, valued at $604,449.78. This represents a 51.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 133,627 shares of company stock valued at $1,325,764. 6.10% of the stock is owned by insiders.

Analysts Set New Price Targets

EOLS has been the topic of a number of analyst reports. Wall Street Zen lowered Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. HC Wainwright dropped their price objective on Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. BTIG Research reaffirmed a "buy" rating and issued a $18.00 target price on shares of Evolus in a research report on Monday. Finally, Needham & Company LLC reissued a "hold" rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.